Some biotech companies can keep 30% to 50% of their drug sales despite generic rivals "if they're smart competitors," Amgen CEO Kevin Sharer told investors. The threat of generic competition is greater for conventional medicines because it could cost drugmakers as much as 90% of sales in one year once a copycat version is launched, Sharer said.

Full Story:

Related Summaries